Abbott delivers $12.6 billion second quarter sales

• Abbott reported $12.6 billion in second-quarter sales and raised its full-year adjusted earnings guidance.
• The company shares traded higher in the broader market following the financial performance announcement.
• The business stated that the updated outlook reflects strong diagnostics and medical devices sales growth.

Abbott (NYSE:ABT) reported second-quarter 2026 sales of $12.6 billion and an adjusted earnings of $1.31 per diluted share.

The financial performance represents a 13 percent reported sales increase and a 4.8 percent comparable growth rate.

The company recorded a 42.3 percent reported increase in diagnostics sales alongside a 9 percent growth in its medical devices segment.

The business returned $2.1 billion to shareholders through dividends and share buybacks while officially declaring its 410th consecutive quarterly dividend.

Management expects third-quarter adjusted earnings to range between $1.38 and $1.46 per share.

The healthcare enterprise also finalized enrollment in its TECTONIC pivotal trial and officially secured the CE Mark for its Libre Duo product.

The company stated that the established pharmaceuticals division generated an 8.4 percent reported sales growth to partially offset declines across the nutrition segment.